Multimodal Deep Learning for the Diagnosis and Assessment of Alzheimer's Disease
NCT ID: NCT06081569
Last Updated: 2023-10-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Total Enrollment
300 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-10-15
Study Completion Date
2026-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Alzheimer's disease (AD) is the most common dementia and has been one of the most expensive diseases with the highest lethality. With the rapid increase of the aging population, more and more burdens will be posed on society and economics. The manifestations of AD are the progressive loss of memory, language and visuospatial function, executive and daily living abilities, and so forth. The Pathophysiological changes of AD occur 10-20 years before the clinical symptoms, while there is still a lack of effective strategy for early diagnosis. Mild cognitive impairment (MCI) is considered to be a transitional state between healthy aging and the clinical diagnosis of dementia and has received increasing attention as a separate diagnostic entity.
To make the diagnosis, doctors ought to compressively consider the multimodal medical information including clinical symptoms, neuroimages, neuropsychological tests, laboratory examinations, etc. Multimodal deep learning has risen to this challengeļ¼ which could integrate the various modalities of biological information and capture the relationships among them contributing to higher accuracy and efficiency. It has been widely applied in imaging, tumor pathology, genomics, etc. Recently, the studies on AD based on deep learning still mainly focused on multimodal neuroimaging, while multimodal medical information requires comprehensive integration and intellectual analysis. Moreover, studies reveal that some imperceptible symptoms in MCI and the early stage of AD may also play an effective role in diagnosis and assessment, such as gait disorder, facial expression identification dysfunction, and speech and language impairment. However, doctors could hardly detect the slight and complex changes, which could rely on the full mining of the video and audio information by multimodal deep learning.
In conclusion, we aim to explore the features of gait disorder, facial expression identification dysfunction, and speech and language impairment in MCI and AD, and analyze their diagnostic efficiency. We would identify the different degrees of dependency on multimodal medical information in diagnosis and finally build an optimal multimodal diagnostic method utilizing the most convenient and economical information. Besides, based on follow-up observations on the changes in multimodal medical information with the progress of AD and MCI, we expect to establish an effective and convenient diagnostic strategy.
To make the diagnosis, doctors ought to compressively consider the multimodal medical information including clinical symptoms, neuroimages, neuropsychological tests, laboratory examinations, etc. Multimodal deep learning has risen to this challengeļ¼ which could integrate the various modalities of biological information and capture the relationships among them contributing to higher accuracy and efficiency. It has been widely applied in imaging, tumor pathology, genomics, etc. Recently, the studies on AD based on deep learning still mainly focused on multimodal neuroimaging, while multimodal medical information requires comprehensive integration and intellectual analysis. Moreover, studies reveal that some imperceptible symptoms in MCI and the early stage of AD may also play an effective role in diagnosis and assessment, such as gait disorder, facial expression identification dysfunction, and speech and language impairment. However, doctors could hardly detect the slight and complex changes, which could rely on the full mining of the video and audio information by multimodal deep learning.
In conclusion, we aim to explore the features of gait disorder, facial expression identification dysfunction, and speech and language impairment in MCI and AD, and analyze their diagnostic efficiency. We would identify the different degrees of dependency on multimodal medical information in diagnosis and finally build an optimal multimodal diagnostic method utilizing the most convenient and economical information. Besides, based on follow-up observations on the changes in multimodal medical information with the progress of AD and MCI, we expect to establish an effective and convenient diagnostic strategy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of the Digital Multi-domain Cognitive Intervention in High-risk Populations for Dementia
NCT06442943
Cognitive Dysfunction
RECRUITING
NA
Developing an Artificial Intelligence System to Detect Cognitive Impairment
NCT05794451
Alzheimer Disease
Healthy Aging
Mild Cognitive Impairment
RECRUITING
Application of AI Technology for the Diagnosis and Treatment of Geriatric Diseases
NCT06295263
Parkinson Disease
Alzheimer Disease
Nervous System Diseases
+1 more
RECRUITING
Digital Technology Combined With Blood Marker Screening and Diagnosis for Community Populations Based on Classification Theory: an Integrated Study
NCT07286812
Alzheimer Disease
NOT_YET_RECRUITING
Effects of Multidomain Intervention on Cognitive Function in Community-dwelling Elderly
NCT06180161
Cognitive Decline
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Our objective is to make the early diagnosis and assessment of AD and MCI based on multimodal deep learning. Initially, Gait disorder, facial expression identification dysfunction, and speech and language impairment are of great significance in the occurrence and development of AD and MCI. However, due to the high complexity and stealthiness of these clinical symptoms, no uniform conclusions have been made. Hence, we attempt to apply machine learning methods to recognize the video and audio information. In this way, we will explore the changing characteristics of gait, expression, and language in AD and MCI, and analyze their diagnostic effectiveness as diagnostic markers, finally providing new ideas and experimental data for the diagnosis of AD and MCI. Secondly, multimodal medical information needs to be integrated and comprehensively analyzed. We aim to propose an optimal diagnostic strategy referring to the different degrees of dependency on multimodal medical information in diagnosis. Moreover, observing the changes in multimodal medical information with the progress of AD and MCI, we expect to build a predicting model of AD diagnosis and prognosis.
The methods are as follows:
1. Collecting multimodal medical information A variety of multimodal medical information would be carefully collected including the baseline demographic data, chief complaint and medical history, peripheral organ function assessment, laboratory examination, imaging examination, neuroelectrophysiological examination, neurocognitive and psychological examination, information on gait, expression, and language, and biological samples, etc.
2. Revealing the changes of gait, expression, and language in patients with AD and MCI, and verifying their diagnostic efficacy.
For multimodal medical information on gait, OpenPose model was used to extract human key points and construct a human skeleton structure diagram. Based on graph neural networks and convolutional neural networks, instantaneous action analysis of single-frame images is carried out. And then utilizing the Transformer model, gait sequence analysis is carried out by integrating multi-frame video.For multimodal medical information on facial expression, the Dlib algorithm will be used to extract facial key points, combined with facial expression images, and the spatiotemporal Transformer model will be used for facial expression analysis. For multimodal medical information on language, ASRT model will be used for speech recognition and text content extraction. Simultaneously, the frequency domain Fourier transform and wavelet transform will be applied to extract frequency domain information and analyze the speech features by integrating language content, voice intonation, speech speed, and other information. Based on the attention model, the gait, expression, and language analysis results of AD and MCI will be compared with those of the control group to reveal the features of AD and MCI and provide evidence for disease diagnosis.
3. Analyzing the different degrees of dependency on multimodal information in the diagnosis of AD and MCI diseases, and establishing an optimal diagnosis strategy In the supervised learning process, the attention mechanism-based method will be used to analyze the influence of multimodal information on the final results. At the same time, based on the knowledge map, the patient's blood biochemical indicators, genomic information and other fields of knowledge would be added to the model. Based on Bayesian probability inference and causal inference theory, the causal programming method will be used to model the causal analysis of information and diagnosis results of different modes. Based on AutoML method, multimodal information will be combined and optimized, and a reliable optimal diagnosis strategy will be established according to experimental results.
4. Exploring the changes of multimodal medical information with the progression of the disease, and build a predicting model for early diagnosis and disease progression of AD.
Viewing multimodal medical information as the control condition, the Transformer model will be used to model time sequence information, and the conditional diffusion model will be used to generate patients' MRI image changes and other disease progression-related information, providing the basis for disease progression prediction. Based on the large multimodal model technology, the output of the model will be interfered with and adjusted referring to the judgment and description of professional doctors, to generate the prediction in line with the judgment of professional doctors, and finally construct the interpretable early diagnosis and disease progression prediction model.
The methods are as follows:
1. Collecting multimodal medical information A variety of multimodal medical information would be carefully collected including the baseline demographic data, chief complaint and medical history, peripheral organ function assessment, laboratory examination, imaging examination, neuroelectrophysiological examination, neurocognitive and psychological examination, information on gait, expression, and language, and biological samples, etc.
2. Revealing the changes of gait, expression, and language in patients with AD and MCI, and verifying their diagnostic efficacy.
For multimodal medical information on gait, OpenPose model was used to extract human key points and construct a human skeleton structure diagram. Based on graph neural networks and convolutional neural networks, instantaneous action analysis of single-frame images is carried out. And then utilizing the Transformer model, gait sequence analysis is carried out by integrating multi-frame video.For multimodal medical information on facial expression, the Dlib algorithm will be used to extract facial key points, combined with facial expression images, and the spatiotemporal Transformer model will be used for facial expression analysis. For multimodal medical information on language, ASRT model will be used for speech recognition and text content extraction. Simultaneously, the frequency domain Fourier transform and wavelet transform will be applied to extract frequency domain information and analyze the speech features by integrating language content, voice intonation, speech speed, and other information. Based on the attention model, the gait, expression, and language analysis results of AD and MCI will be compared with those of the control group to reveal the features of AD and MCI and provide evidence for disease diagnosis.
3. Analyzing the different degrees of dependency on multimodal information in the diagnosis of AD and MCI diseases, and establishing an optimal diagnosis strategy In the supervised learning process, the attention mechanism-based method will be used to analyze the influence of multimodal information on the final results. At the same time, based on the knowledge map, the patient's blood biochemical indicators, genomic information and other fields of knowledge would be added to the model. Based on Bayesian probability inference and causal inference theory, the causal programming method will be used to model the causal analysis of information and diagnosis results of different modes. Based on AutoML method, multimodal information will be combined and optimized, and a reliable optimal diagnosis strategy will be established according to experimental results.
4. Exploring the changes of multimodal medical information with the progression of the disease, and build a predicting model for early diagnosis and disease progression of AD.
Viewing multimodal medical information as the control condition, the Transformer model will be used to model time sequence information, and the conditional diffusion model will be used to generate patients' MRI image changes and other disease progression-related information, providing the basis for disease progression prediction. Based on the large multimodal model technology, the output of the model will be interfered with and adjusted referring to the judgment and description of professional doctors, to generate the prediction in line with the judgment of professional doctors, and finally construct the interpretable early diagnosis and disease progression prediction model.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alzheimer Disease
Mild Cognitive Impairment
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alzheimer's disease
the diagnosis of AD is according to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for AD.
gait video; speech video; facial expression video;
Intervention Type
DIAGNOSTIC_TEST
The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
Mild cognitive impairment
the diagnosis of MCI refers to the criteria defined by Peterson in 2004.
gait video; speech video; facial expression video;
Intervention Type
DIAGNOSTIC_TEST
The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
Control
participants who are age-matched with AD and MCI participants, without cognitive impairment.
gait video; speech video; facial expression video;
Intervention Type
DIAGNOSTIC_TEST
The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gait video; speech video; facial expression video;
The videos of participants' gait, facial expression, and speech will be recorded and analyzed further. Other routine diagnostic tests will also be performed such as imaging of MRI, cognitive scales, etc.
Intervention Type
DIAGNOSTIC_TEST
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Other routine diagnostic tests such as imaging, cognitive scales, etc.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. . Participants' age is between 50 and 85 years old, male or female;
2. . Participants graduated from primary school or above, with normal hearing, vision, and pronunciation, using Chinese as their mother tongue and Mandarin as their daily languageļ¼
3. . The diagnosis of AD and MCI participants conform to the corresponding diagnostic criteria mentioned above;
4. . The scores of MMSE are between 10 and 28, and the scores of CDR are no more than 2.
5. . Patients or family members agree to sign informed consent.
2. . Participants graduated from primary school or above, with normal hearing, vision, and pronunciation, using Chinese as their mother tongue and Mandarin as their daily languageļ¼
3. . The diagnosis of AD and MCI participants conform to the corresponding diagnostic criteria mentioned above;
4. . The scores of MMSE are between 10 and 28, and the scores of CDR are no more than 2.
5. . Patients or family members agree to sign informed consent.
Exclusion Criteria
1. . Participants suffer from neurological disorders that could cause dysfunction of the brain, such as depression, tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal cranial pressure hydrocephalus, and so forth;
2. . Participants suffer from systematic diseases that could cause cognitive impairment, such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, and so forth;
3. . Participants suffer from diseases that are unable to cooperate with the examinations;
4. . Participants cannot take magnetic resonance imaging;
5. . Participants suffer from mental and neurodevelopmental retardation;
6. . Participants refuse to sign informed consent.
2. . Participants suffer from systematic diseases that could cause cognitive impairment, such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, and so forth;
3. . Participants suffer from diseases that are unable to cooperate with the examinations;
4. . Participants cannot take magnetic resonance imaging;
5. . Participants suffer from mental and neurodevelopmental retardation;
6. . Participants refuse to sign informed consent.
Minimum Eligible Age
50 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Hospital of China Medical University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liu Huayan
Neurology department
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Huayan Liu
Role: STUDY_CHAIR
the first affiliated hospital of China medical university, neurology department
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer's disease. Lancet. 2021 Apr 24;397(10284):1577-1590. doi: 10.1016/S0140-6736(20)32205-4. Epub 2021 Mar 2.
Reference Type
BACKGROUND
2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14.
Reference Type
BACKGROUND
Knopman DS, Amieva H, Petersen RC, Chetelat G, Holtzman DM, Hyman BT, Nixon RA, Jones DT. Alzheimer disease. Nat Rev Dis Primers. 2021 May 13;7(1):33. doi: 10.1038/s41572-021-00269-y.
Reference Type
BACKGROUND
Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, Zhao L, Jin H, Xu H, Wang F, Zhou A, Zuo X, Wu L, Han Y, Han Y, Huang L, Wang Q, Li D, Chu C, Shi L, Gong M, Du Y, Zhang J, Zhang J, Zhou C, Lv J, Lv Y, Xie H, Ji Y, Li F, Yu E, Luo B, Wang Y, Yang S, Qu Q, Guo Q, Liang F, Zhang J, Tan L, Shen L, Zhang K, Zhang J, Peng D, Tang M, Lv P, Fang B, Chu L, Jia L, Gauthier S. The cost of Alzheimer's disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018 Apr;14(4):483-491. doi: 10.1016/j.jalz.2017.12.006. Epub 2018 Feb 9.
Reference Type
BACKGROUND
Wilson J, Allcock L, Mc Ardle R, Taylor JP, Rochester L. The neural correlates of discrete gait characteristics in ageing: A structured review. Neurosci Biobehav Rev. 2019 May;100:344-369. doi: 10.1016/j.neubiorev.2018.12.017. Epub 2018 Dec 13.
Reference Type
BACKGROUND
Beauchet O, Launay CP, Annweiler C, Allali G. Hippocampal volume, early cognitive decline and gait variability: which association? Exp Gerontol. 2015 Jan;61:98-104. doi: 10.1016/j.exger.2014.11.002. Epub 2014 Nov 6.
Reference Type
BACKGROUND
Ceresetti R, Rouch I, Laurent B, Getenet JC, Pommier M, de Chalvron S, Chainay H, Borg C. Processing of Facial Expressions of Emotions and Pain in Alzheimer's Disease. J Alzheimers Dis. 2022;89(1):389-398. doi: 10.3233/JAD-220236.
Reference Type
BACKGROUND
Klein-Koerkamp Y, Beaudoin M, Baciu M, Hot P. Emotional decoding abilities in Alzheimer's disease: a meta-analysis. J Alzheimers Dis. 2012;32(1):109-25. doi: 10.3233/JAD-2012-120553.
Reference Type
BACKGROUND
Rosen HJ, Wilson MR, Schauer GF, Allison S, Gorno-Tempini ML, Pace-Savitsky C, Kramer JH, Levenson RW, Weiner M, Miller BL. Neuroanatomical correlates of impaired recognition of emotion in dementia. Neuropsychologia. 2006;44(3):365-73. doi: 10.1016/j.neuropsychologia.2005.06.012. Epub 2005 Sep 9.
Reference Type
BACKGROUND
Adolphs R, Tranel D. Impaired judgments of sadness but not happiness following bilateral amygdala damage. J Cogn Neurosci. 2004 Apr;16(3):453-62. doi: 10.1162/089892904322926782.
Reference Type
BACKGROUND
Yamaguchi T, Maki Y, Yamaguchi H. Yamaguchi Facial Expression-Making Task in Alzheimer's Disease: A Novel and Enjoyable Make-a-Face Game. Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):248-57. doi: 10.1159/000339425. Epub 2012 Jun 20.
Reference Type
BACKGROUND
Eyigoz E, Mathur S, Santamaria M, Cecchi G, Naylor M. Linguistic markers predict onset of Alzheimer's disease. EClinicalMedicine. 2020 Oct 22;28:100583. doi: 10.1016/j.eclinm.2020.100583. eCollection 2020 Nov.
Reference Type
BACKGROUND
Ahmed S, Haigh AM, de Jager CA, Garrard P. Connected speech as a marker of disease progression in autopsy-proven Alzheimer's disease. Brain. 2013 Dec;136(Pt 12):3727-37. doi: 10.1093/brain/awt269. Epub 2013 Oct 18.
Reference Type
BACKGROUND
Pakhomov SV, Hemmy LS. A computational linguistic measure of clustering behavior on semantic verbal fluency task predicts risk of future dementia in the nun study. Cortex. 2014 Jun;55:97-106. doi: 10.1016/j.cortex.2013.05.009. Epub 2013 Jun 14.
Reference Type
BACKGROUND
Green S, Reivonen S, Rutter LM, Nouzova E, Duncan N, Clarke C, MacLullich AMJ, Tieges Z. Investigating speech and language impairments in delirium: A preliminary case-control study. PLoS One. 2018 Nov 26;13(11):e0207527. doi: 10.1371/journal.pone.0207527. eCollection 2018.
Reference Type
BACKGROUND
Wilson SM, Eriksson DK, Schneck SM, Lucanie JM. A quick aphasia battery for efficient, reliable, and multidimensional assessment of language function. PLoS One. 2018 Feb 9;13(2):e0192773. doi: 10.1371/journal.pone.0192773. eCollection 2018.
Reference Type
BACKGROUND
Chen X, Wang X, Zhang K, Fung KM, Thai TC, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y. Recent advances and clinical applications of deep learning in medical image analysis. Med Image Anal. 2022 Jul;79:102444. doi: 10.1016/j.media.2022.102444. Epub 2022 Apr 4.
Reference Type
BACKGROUND
Jiang Y, Yang M, Wang S, Li X, Sun Y. Emerging role of deep learning-based artificial intelligence in tumor pathology. Cancer Commun (Lond). 2020 Apr;40(4):154-166. doi: 10.1002/cac2.12012. Epub 2020 Apr 11.
Reference Type
BACKGROUND
Hu X, Fernie AR, Yan J. Deep learning in regulatory genomics: from identification to design. Curr Opin Biotechnol. 2023 Feb;79:102887. doi: 10.1016/j.copbio.2022.102887. Epub 2023 Jan 12.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LHuayan
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Cohort Study on Cognitive Decline in Elderly
NCT07093892
NOT_YET_RECRUITING
Multimodal Assesment of Alzheimer Patients
NCT06448403
RECRUITING
Preliminary Research Using Artificial Intelligence Technology to Identify Differences in Facial Expressions Between Healthy People, Patients With Cognitive Decline, and Patients With Dementia
NCT06513403
RECRUITING
Spatial Navigation for the Early Detection of Alzheimer's Disease.
NCT06385951
RECRUITING
NA
The Chinese Familial Alzheimer's Network
NCT03657732
RECRUITING
Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression
NCT01642420
UNKNOWN
PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With Machine Learning
NCT05569083
UNKNOWN
Preventing Alzheimer's With Cognitive Training
NCT03848312
RECRUITING
PHASE3
China Alzheimer's and Neurodegenerative Disorder Research
NCT04320368
UNKNOWN
Language, Speech and Motor Function in MCI Due to AD and Alzheimer's Disease
NCT06508268
RECRUITING
Identifying Biomarkers in Alzheimer's Disease
NCT05655650
RECRUITING
On Site Sensors Monitoring Impacts of Cognitive Decline on ADLs
NCT04871698
UNKNOWN
Contribution of Actigraphy and Recognition Video in Apathy Assessment of Alzheimer's Disease : Experimental Research
NCT01049555
COMPLETED
NA
Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease
NCT01450891
COMPLETED
Metacognition in Semantic Dementia: Comparison With Alzheimer's Disease
NCT04597827
COMPLETED
Multicomponent Exercise in People With Dementia
NCT04951258
UNKNOWN
NA
Cognitive Decline in AD
NCT03946930
RECRUITING
Spatial and Ocular Trajectories for the Early Diagnosis of Alzheimer's Disease.
NCT06213766
NOT_YET_RECRUITING
NA
Cognitive Impairment in Ageing People
NCT04360200
RECRUITING
Cognitive Stimulation in Older Adults With Alzheimer's Disease
NCT07041008
RECRUITING
NA
Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.
NCT03851523
RECRUITING
The China Longitudinal Aging Study of Cognitive Impairment
NCT03672448
UNKNOWN
Monetary Cost of Alzheimer's Disease in China
NCT02694445
COMPLETED
Association of Cognition With Functional Mobility in People With Alzheimer's Disease
NCT05113732
UNKNOWN
Detecting Dementia Earlier
NCT03900936
UNKNOWN